Logistic regression analysis for predictors of hospital utilization for hypoglycemia in 2014
Characteristic | n (%) (n=290 075) | OR (95% CI) Model 1* | P value | OR (95% CI) Model 2* | P value |
Age category (years) | <0.001 | <0.001 | |||
18–39 | 16 628 (5.7) | 2.22 (1.69 to 3.03) | 2.43 (1.78 to 3.31) | ||
40–64 | 137 133 (47.3) | Reference | Reference | ||
65–74 | 74 940 (25.8) | 0.84 (0.65 to 1.10) | 0.74 (0.57 to 0.97) | ||
≥75 | 61 374 (21.2) | 0.99 (0.76 to 1.30) | 0.74 (0.56 to 0.99) | ||
Female sex (reference: Male) | 152 269 (52.5) | 1.32 (1.08 to 1.61) | 0.007 | 1.43 (1.16 to 1.75) | <0.001 |
Race/ethnicity | <0.001 | <0.001 | |||
White, non-Hispanic | 221 863 (76.5) | Reference | Reference | ||
Black, non-Hispanic | 43 971 (15.2) | 2.16 (1.67 to 2.78) | 1.84 (1.43 to 2.38) | ||
Other, non-Hispanic | 7663 (2.6) | 1.09 (0.55 to 2.15) | 1.20 (0.61 to 2.37) | ||
Hispanic | 13 344 (4.6) | 1.67 (0.97 to 2.86) | 1.59 (0.93 to 2.71) | ||
Missing | 3234 (1.1) | 0.34 (0.48 to 2.44) | 0.35 (0.05 to 2.50) | ||
Diabetes medication category | <0.001 | <0.001 | |||
No medication | 149 203 (51.4) | Reference | Reference | ||
Low-risk medication | 55 505 (19.1) | 0.40 (0.27 to 0.60) | 0.44 (0.29 to 0.67 | ||
High-risk oral medication† | 34 647 (11.9) | 0.83 (0.57 to 1.22) | 0.83 (0.56 to 1.23) | ||
Insulin | 50 720 (17.5) | 2.68 (2.15 to 3.33) | 2.13 (1.67 to 2.73) | ||
Chronic kidney disease | 64 436 (22.2) | 3.68 (3.00 to 4.52) | <0.001 | 2.86 (2.33 to 3.57) | <0.001 |
Cognitive impairment | 14 751 (5.1) | 2.57 (1.85 to 3.56) | <0.001 | 1.92 (1.39 to 2.70) | <0.001 |
HbA1c category | <0.001 | <0.001 | |||
<6.0% | 23 491 (8.1) | 2.30 (1.55 to 3.42) | 2.00 (1.33 to 2.94) | ||
6.0%–6.9% | 59 293 (20.4) | Reference | Reference | ||
7.0%–7.9% | 35 571 (12.3) | 1.71 (1.16 to 2.52) | 1.39 (0.94 to 2.08) | ||
8.0%–8.9% | 17 883 (6.2) | 1.85 (1.16 to 2.93) | 1.20 (0.75 to 1.92) | ||
≥9.0% | 24 616 (8.5) | 2.69 (1.84 to 3.92) | 1.56 (1.05 to 2.33) | ||
Missing | 129 221 (44.6) | 1.38 (1.01 to 1.90) | 1.33 (0.97 to 1.85) |
*Model 1 adjusted for age, sex, race/ethnicity and study site. Model 2 adjusted for model 1+diabetes medication category, chronic kidney disease, cognitive impairment, and HbA1c category.
†Sulfonylurea or meglitinide.
HbA1c, hemoglobin A1c.